The Russian science, technology and innovation (STI) system is geared towards global geoeconomic competitiveness and is based on three S’s: state control, sovereignty and self-sufficiency.
State-sponsored biotechnological innovation is a component in Russia’s geoeconomic strategy: in the case of Sputnik V, Russia’s commercial and strategic objectives are intertwined.
The Russian state’s close involvement in development, marketing and propagating Sputnik V – as well as its readiness to skip standard practices in order to make headway with the product – create well-founded distrust towards it in Western markets.
In the emerging and developing markets, Sputnik V suffers from insufficient manufacturing capacity. In many countries, only a fraction of promised doses have been delivered, and setting up local manufacturing capacity outside the EAEU takes time.
The European states should pay more attention to linkages between Russian innovation policies and its foreign, security and military policies. For Russia, these are not separate silos but build upon and support each other.